Author(s) Details:
Khaled Jadallah
Department of Internal Medicine, King Abdullah University Hospital, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
Roberto De Giorgio
Department of Translational Sciences, University of Ferrara, Ferrara, Italy.
Rami Jadallah
Department of Internal Medicine, King Abdullah University Hospital, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
This section is a part of the chapter: Pharmacological Ad-vancements in the Management of Constipation-Predominant Irritable Bowel Syndrome: A Comprehensive Review
The IBS-C subtype affects a significant number of patients, particularly older adults and those from lower socioeconomic backgrounds. Recent studies indicate that IBS-C is linked to higher levels of functional impairment compared to other subtypes of IBS.
Conventional pharmacological and non-pharmacological treatment options for IBS-C have limited effectiveness and may cause significant adverse effects. This results in higher long-term healthcare costs. Over the past few decades, the ineffectiveness in treating patients with IBS-C has largely stemmed from a poor understanding of the disease’s pathophysiology, a failure to consider the patient as a whole, and inappropriate patient selection and treatment endpoints in clinical trials.
How to Cite
Jadallah, K., Giorgio, R. D., & Jadallah, R. (2025). Pharmacological Advancements in the Management of Constipation-Predominant Irritable Bowel Syndrome: A Comprehensive Review. Medical Science: Trends and Innovations Vol. 4, 49–85. https://doi.org/10.9734/bpi/msti/v4/4177